The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.
【저자키워드】 Infectious diseases, Drug development, 【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, clinical trial, pandemic, Anti-inflammatory, Vaccines, Infection, clinical trials, Estrogen, Prophylactic, virus, attack rate, eradication, immune memory, respiratory, COVID-19 patients, raloxifene, acute respiratory syndrome, estrogen receptor, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, candidate, antiviral properties, clinical development, endurance, selective, identify, caused, therapeutic drug, 【제목키워드】 SARS-COV-2 infection, repurposing, estrogen receptor, treat,